Synthasome

Executive Summary

Synthasome Inc. is a San Diego-based orthobiologics company developing products for soft tissue and cartilage regeneration. Founded in 2004, its lead product X-Repair is a surgical mesh intended to reinforce tendon and soft tissue repairs, aiming to improve surgical outcomes and reduce healing times. The company targets unmet needs in orthopedic and musculoskeletal applications. While Synthasome has been operating for over two decades, it remains private with limited public disclosure on funding or milestones. Its focus on regenerative medicine and medical devices places it in a growing market, yet the lack of recent commercial traction or clinical updates suggests a cautious outlook. The company's success hinges on regulatory clearances and adoption of X-Repair in a competitive landscape dominated by established players.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) Clearance for X-Repair70% success
• Q2 2027Clinical Trial Results for Tendon Repair50% success
• Q3 2026Strategic Partnership or Distribution Agreement40% success